KCNB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13077332	0.60	13/20
SCHEMBL15533358	0.52	9/20
SCHEMBL15533086	0.49	9/20
SCHEMBL15533539	0.49	9/20
SCHEMBL15534015	0.48	9/20
SCHEMBL15532900	0.47	9/20
SCHEMBL15534384	0.43	9/20
SCHEMBL15534214	0.52	8/20
SCHEMBL16714194	0.50	8/20
SCHEMBL5217898	0.49	8/20
SCHEMBL5217905	0.49	8/20
SCHEMBL5217913	0.49	8/20
SCHEMBL5221624	0.49	8/20
SCHEMBL15533140	0.49	8/20
SCHEMBL15533793	0.49	8/20
SCHEMBL15534547	0.49	8/20
SCHEMBL15533437	0.48	8/20
SCHEMBL15533084	0.47	8/20
SCHEMBL15533930	0.47	8/20
SCHEMBL15533186	0.46	8/20

Clinical trials — most relevant to KCNB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease	PHASE4	NOT_YET_RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes	PHASE4	UNKNOWN
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy	nan	UNKNOWN
Gene Study for Infantile Onset Diabetes	nan	UNKNOWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNB1 binder may also engage these)

Protein	Name	Similarity
Q03717	—	1.000	Q03717 →
O18868	—	1.000	O18868 →
A6H8H5	—	1.000	A6H8H5 →
Q9MZ19	—	1.000	Q9MZ19 →
Q63099	—	1.000	Q63099 →
P15387	—	1.000	P15387 →
Q4ZHA6	—	1.000	Q4ZHA6 →
Q95167	—	1.000	Q95167 →
Q95L11	—	0.997	Q95L11 →
KCNB2	Potassium voltage-gated channel subfamily B member 2	0.996	landscape →
Q9Z0V1	—	0.993	Q9Z0V1 →
Q62897	—	0.992	Q62897 →
KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	0.992	landscape →
O88944	—	0.991	O88944 →
Q8K3F6	—	0.991	Q8K3F6 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	0.991	landscape →
Q60603	—	0.990	Q60603 →
Q9TTT5	—	0.990	Q9TTT5 →
Q9Z351	—	0.989	Q9Z351 →
KCND3	A-type voltage-gated potassium channel KCND3	0.989	landscape →
O88943	—	0.989	O88943 →
Q14B80	—	0.988	Q14B80 →
P58126	—	0.988	P58126 →
KAT2B	Histone acetyltransferase KAT2B	0.988	landscape →
HCN1	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	0.988	landscape →
P97414	—	0.988	P97414 →
P25122	—	0.987	P25122 →
Q96PR1	—	0.987	Q96PR1 →
Q9TUI4	—	0.987	Q9TUI4 →
P19024	—	0.987	P19024 →